FDA D.I.S.C.O. Burst Edition: FDA approvals of Jemperli (dostarlimab-gxly) for patients with mismatch repair deficient recurrent or advanced solid tumors, and Opdivo (nivolumab) for the adjuvant treatment of patients with urothelial carcinoma
0:00
6:00
Listen to a soundcast of the August 17, 2021, and August 19, 2021, FDA approvals of Jemperli (dostarlimab-gxly) for patients with mismatch repair deficient recurrent or advanced solid tumors, and Opdivo (nivolumab) for the adjuvant treatment of patients with urothelial carcinoma
D'autres épisodes de "FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)"
Ne ratez aucun épisode de “FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)” et abonnez-vous gratuitement à ce podcast dans l'application GetPodcast.